<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xu Y</submitter><funding>Zuochong Yu</funding><pagination>243</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10386629</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Osteosarcoma (OS) is the most prevalent primary malignant bone tumor. However, single-agent chemotherapy exhibits limited efficacy against OS and often encounters tumor resistance. Therefore, we designed and constructed an integrated treatment strategy of photothermal therapy (PTT) combined with chemotherapy and used a surface-encapsulated platelet-osteosarcoma hybrid membrane (OPM) that enhances circulation time and enables OS-specific targeting.&lt;h4>Results&lt;/h4>The OPM functions as a shell structure, encapsulating multiple drug-loaded nanocores (BPQDs-DOX) and controlling the release rate of doxorubicin (DOX). Moreover, near-infrared light irradiation accelerates the release of DOX, thereby extending circulation time and enabling photostimulation-responsive release. The</pubmed_abstract><journal>Journal of nanobiotechnology</journal><pubmed_title>Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma.</pubmed_title><pmcid>PMC10386629</pmcid><funding_grant_id>81602358</funding_grant_id><pubmed_authors>Xia K</pubmed_authors><pubmed_authors>Han B</pubmed_authors><pubmed_authors>Zhai Y</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Yu Z</pubmed_authors><pubmed_authors>Du L</pubmed_authors><pubmed_authors>Fei J</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Black phosphorus quantum dots camouflaged with platelet-osteosarcoma hybrid membrane and doxorubicin for combined therapy of osteosarcoma.</name><description>&lt;h4>Background&lt;/h4>Osteosarcoma (OS) is the most prevalent primary malignant bone tumor. However, single-agent chemotherapy exhibits limited efficacy against OS and often encounters tumor resistance. Therefore, we designed and constructed an integrated treatment strategy of photothermal therapy (PTT) combined with chemotherapy and used a surface-encapsulated platelet-osteosarcoma hybrid membrane (OPM) that enhances circulation time and enables OS-specific targeting.&lt;h4>Results&lt;/h4>The OPM functions as a shell structure, encapsulating multiple drug-loaded nanocores (BPQDs-DOX) and controlling the release rate of doxorubicin (DOX). Moreover, near-infrared light irradiation accelerates the release of DOX, thereby extending circulation time and enabling photostimulation-responsive release. The</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2025-04-27T00:07:23.184Z</modification><creation>2025-04-06T17:45:56.292Z</creation></dates><accession>S-EPMC10386629</accession><cross_references><pubmed>37507707</pubmed><doi>10.1186/s12951-023-02016-9</doi></cross_references></HashMap>